WO2009116801A2 - Caspase inhibitor prodrug - Google Patents
Caspase inhibitor prodrug Download PDFInfo
- Publication number
- WO2009116801A2 WO2009116801A2 PCT/KR2009/001368 KR2009001368W WO2009116801A2 WO 2009116801 A2 WO2009116801 A2 WO 2009116801A2 KR 2009001368 W KR2009001368 W KR 2009001368W WO 2009116801 A2 WO2009116801 A2 WO 2009116801A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compounds
- pharmaceutically acceptable
- acceptable salts
- composition
- Prior art date
Links
- 229940123169 Caspase inhibitor Drugs 0.000 title claims abstract description 11
- 239000000651 prodrug Substances 0.000 title abstract description 8
- 229940002612 prodrug Drugs 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 13
- 208000006454 hepatitis Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 231100000354 acute hepatitis Toxicity 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 3
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 3
- 208000022306 Cerebral injury Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000002547 isoxazolines Chemical class 0.000 abstract description 7
- 102000011727 Caspases Human genes 0.000 description 9
- 108010076667 Caspases Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
Definitions
- the present invention relates to isoxazoline derivatives of the following formula (1):
- R 1 represents isoquinolinyl, quinolinyl or naphthyl
- R 2 represents C 1-8 alkyl, as a prodrug of the caspase inhibitors of the following formula (2):
- R 1 and R 2 are as defined above, and pharmaceutically acceptable salts thereof.
- the present invention also relates to a process for preparing the compounds of formula (1), and caspase inhibitor compositions which comprises the compounds of formula (I) or pharmaceutically acceptable salts thereof as an active ingredient, specifically to compositions for anti-inflammation and the prevention or treatment of apoptosis.
- Caspase is a new kind of cysteine protease recently discovered. About 14 kinds thereof have been known up to now. They are cysteine proteases existing as a tetramer in the form of ⁇ 2 ⁇ 2 .
- Caspase inhibitors mean those compounds that inhibit the activity of caspase, thereby control such symptoms as inflammation, apoptosis, etc. caused by the caspase activity.
- Diseases or symptoms that may be treated or alleviated by administering the inhibitors include the following: dementia, cerebral stroke, brain impairment due to AIDS, diabetes, gastric ulcer, cerebral injury by hepatitis virus, hepatitis-induced hepatic diseases, acute hepatitis, human fulminant hepatic failure, sepsis, organ transplantation rejection, rheumatic arthritis, ischemic cardiac diseases, and liver cirrhosis.
- isoxazoline derivatives have been filed as WO 2006/090997 and WO 2005/021516. Further, caspase inhibitor prodrugs on the basis of isoxazoline derivatives are disclosed in WO 2007/015931 (filed by Vertex Pharmaceuticals Incorporated, USA ).
- the present inventors have tried to develop new prodrugs of the excellent caspase inhibitors having the isoxazoline structure of formula (2), in order to improve the inhibitors' bioavailability.
- the present invention is to provide the compounds of formula (1) or pharmaceutically acceptable salts thereof.
- the present invention also provides a process for preparing the compounds of formula (1).
- the present invention also provides a caspase inhibitor composition, more specifically a composition for anti-inflammation and the prevention or treatment of apoptosis, which comprises the compounds of formula (1) or pharmaceutically acceptable salts thereof as an active ingredient together with a pharmaceutically acceptable carrier.
- Figure 1 represents the X-ray crystalline structure of the compound of formula (1a);
- Figure 2 represents the XRD data of the compound of formula (1a);
- the present invention relates to new compounds of the following formula (1):
- R 1 represents isoquinolinyl, quinolinyl or naphthyl
- R 2 represents C 1-8 alkyl, having a caspase-inhibiting activity.
- preferred compounds are those wherein R 1 represents isoquinolinyl, quinolinyl or naphthyl, and R 2 represents methyl, ethyl, propyl, isopropyl or butyl. More preferred compound is 3a-(fluoromethyl)-2-[(5R)-5-isopropyl-3-isoquinolin-1-yl-4,5-dihydro-isoxazol-5-yl]-6,6a-dihydropuro[3,2-d][1,3]oxazol-5(3aH)-one of the following formula (1a):
- R 1 represents isoquinolinyl and R 2 represents isopropyl.
- the compound of formula (1a) was identified by the X-ray crystallography experiment to have the crystalline structure of Figure 1.
- Figure 2 represents the XRD data showing the crystallinity of the compound of formula (1a).
- the compounds of formula (1) may be used in the form of a pharmaceutically acceptable salt which includes the acid or base addition salt typically known in the art.
- the compounds of formula (1) can be prepared by reacting the compounds of formula (2) with trifluoroacetic anhydride in an organic solvent, as depicted in the following Reaction Scheme (1):
- R 1 and R 2 are as defined above.
- the isoxazoline derivatives of formula (2), the caspase inhibitors are dissolved in an organic solvent such as dichloromethane at 10 ⁇ 40 °C , and trifluoroacetic anhydride is added in an amount of 1 to 5 molar ratio with respect to the isoxazoline derivatives of formula (2) at the same temperature.
- the resulting mixture is reacted for 1 to 48 h to give the compounds of formula (1).
- the compounds of formula (1) according to the present invention act as a prodrug for the caspase inhibitor, which is demonstrated by the results of the following Experiments.
- the compounds of formula (1) are administered into the body, they are converted to their active forms, the compounds of formula (2), and then metabolized in the body. According to this, the compounds of formula (1) can exert the anti-inflammation effect or blocking effect against apoptosis.
- the present invention provides a caspase inhibitor composition, more specifically a composition for anti-inflammation and the prevention or treatment of apoptosis, which comprises the compounds of formula (1) or pharmaceutically acceptable salts thereof as an active ingredient together with a pharmaceutically acceptable carrier. More specifically, the composition of the present invention exhibits the therapeutic or preventive effect against dementia, cerebral stroke, brain impairment due to AIDS, diabetes, gastric ulcer, cerebral injury by hepatitis virus, hepatitis-induced hepatic diseases, acute hepatitis, human fulminant hepatic failure, sepsis, organ transplantation rejection, rheumatic arthritis, necrosis of cardiac cell due to ischemic cardiac diseases, and liver cirrhosis.
- the compounds of the present invention can be formulated as various pharmaceutical dosage forms according to the desired purpose.
- therapeutically effect amounts of the compounds of formula (1) or pharmaceutically acceptable salts thereof are mixed together with various pharmaceutically acceptable carriers which can be selected according to the formulation to be prepared.
- the caspase inhibitor compounds of the present invention can be formulated as injectable, percutaneous or oral preparation according to the desired purpose. It is especially advantageous to prepare the formulation in a unit dosage form for ease of administration and uniformity of dosage.
- any usual pharmaceutical carrier may be used for the oral preparation.
- water, glycols, oils, alcohols and the like may be used for oral liquid preparations such as suspensions, syrups, elixirs and solutions; or starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like may be used for solid preparations such as powders, pills, capsules and tablets. Due to their ease of administration, tablets and capsules are the most advantageous dosage unit forms. It is also desirable for tablets and pills to be formulated into enteric-coated preparation.
- injections for example, sterilized aqueous or oily suspension for injection, can be prepared according to the known procedure using suitable dispersing agent, wetting agent, or suspending agent.
- Solvents that can be used for preparing injections include water, Ringer's fluid, and isotonic NaCl solution, and also sterilized fixing oil may be conveniently used as the solvent or suspending media. Any non-stimulative fixing oil including mono-, di-glyceride may be used for this purpose. Fatty acids such as oleic acid may also be used for injections.
- the carrier may include a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives having no significant skin irritation.
- Said additives may be selected from those which facilitate the administration through the skin and/or assist preparation of a desired composition.
- the compounds of the present invention are preferably administered to the subject patient in a total daily dosage ranging from 5 to 500 mg per kg of body weight.
- the total daily dosage may be administered in a single or multiple dosage.
- specific administration dosage for an individual patient can be varied with body weight, sex, hygienic condition, or diet of subject patient, time or method of administration, excretion rate, mixing ratio of agent, severity of disease to be treated, etc.
- the compound of formula (1a) When the compound of formula (1a) is administered, it is immediately converted to the corresponding active compound of formula (2a), and thus the compound of formula (1a) was not detected in plasma at all. Accordingly, the metabolites of the compound of formula (2a), i.e., compounds of formulas (3) ⁇ (6) were quantitatively analyzed, along with the compound of formula (2a). But, the compound of formula (4) among them was not detected.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080025123A KR20090099886A (ko) | 2008-03-18 | 2008-03-18 | 캐스파제 저해제의 프로드럭 |
KR10-2008-0025123 | 2008-03-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009116801A2 true WO2009116801A2 (en) | 2009-09-24 |
WO2009116801A3 WO2009116801A3 (en) | 2009-12-17 |
Family
ID=41091396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/001368 WO2009116801A2 (en) | 2008-03-18 | 2009-03-18 | Caspase inhibitor prodrug |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20090099886A (ko) |
WO (1) | WO2009116801A2 (ko) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021600A1 (en) * | 1999-09-17 | 2001-03-29 | Lg Chem Investment Ltd. | Caspase inhibitor |
KR100594544B1 (ko) * | 2003-08-27 | 2006-06-30 | 주식회사 엘지생명과학 | 이소옥사졸린 구조를 갖는 캐스파제 저해제 |
KR100774999B1 (ko) * | 2005-02-26 | 2007-11-09 | 주식회사 엘지생명과학 | 이소옥사졸린 유도체 및 그의 제조 방법 |
NZ566022A (en) * | 2005-07-28 | 2011-04-29 | Vertex Pharma | Caspase inhibitor prodrugs |
-
2008
- 2008-03-18 KR KR1020080025123A patent/KR20090099886A/ko not_active Application Discontinuation
-
2009
- 2009-03-18 WO PCT/KR2009/001368 patent/WO2009116801A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2009116801A3 (en) | 2009-12-17 |
KR20090099886A (ko) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930011300B1 (ko) | 옥시인돌유도체 | |
PL184512B1 (pl) | Nowy związek pochodna benzotiazepiny i kompozycja farmaceutyczna | |
US4714762A (en) | Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof | |
US20240158363A1 (en) | Urolithin derivatives and methods of use thereof | |
WO2017047970A1 (ko) | 리나글립틴 결정형 및 이의 제조방법 | |
KR100215346B1 (ko) | 피소스티그민에 관련된 아미노카보닐 카바메이트 및 이의 제조방법 | |
JPH0625091B2 (ja) | ジヒドロジベンゾシクロヘプチリデン―エチルアミン誘導体その製法ならびに医薬組成物 | |
WO2009119980A2 (ko) | 미세소관 형성 저해제로서 유용한 벤조페논 티아졸 유도체 및 이의 제조 방법 | |
CA2022488C (en) | 2,3-dihydro-1-(pyridinylamino)-indoles, a process for their preparation and their use as medicaments | |
CA1327799C (en) | Piperazinecarboxylic acid, its preparation and pharmaceutical compositions containing it | |
WO2009116801A2 (en) | Caspase inhibitor prodrug | |
EP3380482A1 (en) | Crystalline forms of thienopyrimidine compound | |
EP0039919B1 (en) | Benzoxazole and benzothiazole derivatives with anti-allergic activity | |
JPS63119455A (ja) | グリシン誘導体 | |
WO2020159228A1 (ko) | 모노메틸 푸마레이트 전구체 약물 화합물 및 이들의 약학적 조성물 | |
HU185224B (en) | Process for preparing 1-/8-quinolyl/-2-pyrrolidinone and acid addition salts thereof | |
WO2012157977A2 (en) | Manufacturing method of heterocyclic compound | |
CA1137489A (en) | Derivatives of 1,2,3,3a,8,8a-hexadydropyrrolo (2,3-b) indole | |
CA2035397C (en) | Hexahydropyrrolo¬2,3-b|indole carbamates, -ureas, -amides and related compounds, a process for their preparation and their use as medicaments | |
WO2010062147A2 (ko) | 아데포버 디피복실의 결정형, 그 제조방법 및 그를 포함하는 약제학적 조성물 | |
JPH06116273A (ja) | 三環系化合物 | |
JPH08217672A (ja) | キサントン誘導体を含有する抗ヘリコバクター・ピロリ薬 | |
US4405633A (en) | Method of treatment of asthma | |
US5338746A (en) | Thiosemicarbazonic acid esters | |
KR940004059B1 (ko) | 비시클로락탐유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09722822 Country of ref document: EP Kind code of ref document: A2 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09722822 Country of ref document: EP Kind code of ref document: A2 |